Mandate

VINGE ADVISES HEXATRONIC IN CONJUNCTION WITH ACQUISITION OF TD FIBEROPTIK

March 02, 2015

Vinge has advised Hexatronic Group AB (publ) listed on NASDAQ Stockholm First North in conjunction with the acquisition of all shares in Tele & Data Fiberteknik I Örebro AB. TD Fiberoptik manufactures and sells products and solutions for passive fiber networks primarily for the telecommunications market.  TD Fiberoptik has approximately 50 employees in Sweden and Norway and an annual turnover of approximately SEK 125 million with an EBITDA margin of approximately 12 per cent.

The purchase price on a debt free basis amounts to approximately SEK 80 million, approximately SEK 70 million of which is paid in cash and approximately SEK 10 million through in issue in kind to the seller.

Vinge’s team consisted of responsible partner Anders Strid together with, among others, associates Amanda Winberg (project manager), Frida Bäckergren, Frida Mattsson (employment), Karin Wissenius (competition) and corporate assistant, Josefine Halldén.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026